Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor‐dependent, transcription‐independent mechanism
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Recruitment to activated tyrosine kinase growth factor receptors of Grb2 and p21(ras) leads to downstream activation of the kinases Raf, MAPK/Erk kinase (Mek) and, subsequently, extracellular signal-regulated kinase (Erk). Activated Erk phosphorylates specific serine residues within cytosolic phospholipase A(2) (PLA(2)), promoting enzyme translocation to membranes and facilitating liberation of arachidonic acid (AA). In the A549 human adenocarcinoma cell line dexamethasone inhibited epidermal growth factor (EGF)-stimulated cytosolic PLA(2) (cPLA(2)) activation and AA release by blocking the recruitment of Grb2 to the activated EGF receptor (EGF-R) through a glucocorticoid receptor (GR)-dependent (RU486-sensitive), transcription-independent (actinomycin-insensitive), mechanism. The dexamethasone-induced block of Grb2 recruitment was parallelled by changes in phosphorylation status and subcellular localization of lipocortin 1 (LC1) and an increase in the amount of the tyrosine phosphoprotein co-localized with EGF-R. Like dexamethasone, peptides containing E-Q-E-Y-V from the N-terminal domain of LC1 also blocked ligand-induced association of Grb2, p21(ras) and Raf. Our results point to an unsuspected rapid effect of glucocorticoids, mediated by occupation of GR but not by changes in gene transcription, which is brought about by competition between LC1 and Grb2 leading to a failure of recruitment off signalling factors to EGF-R
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Binding of glucocorticoids to GR not only activates the receptor, but also liberates accessory proteins that participate in secondary signaling cascades.”
From Corticosteroids (2016) · cites this paper as [38]
In the citing paper
“For example, when released from the inactive GR protein complex, c-Src activates signaling cascades that inhibit phospholipase A2 activity, phosphorylate annexin 1, and impair the release of arachidonic acid38, 39.”
From Corticosteroids (2016) · cites this paper as [38]
Citations
Cites
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
cPLA2 is phosphorylated and activated by MAP kinase
Lin, L.-L., Wartmann, M., Lin, A. Y., Knopf, J. L., Seth, A., & Davis, R. J. (1993) · Cell · doi:10.1016/0092-8674(93)90666-e · Cited by 1,849 · cited 1×
“Activated Erk phosphorylates speci®c serine (Ser) residues within cytosolic phospholipase A2 (cPLA2), promoting enzyme translocation to membranes and facilitating liberation of arachidonic acid (AA) (Lin et al., 1993).”
BackgroundDNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 1×
“A recent study, for example, showed that, in contrast to the lethal nature of a GR knock-out, mice bearing a mutation of the GR which disabled dimerization, and hence GRE binding, survived (Reichardt et al., 1998).”
ResultTyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959 · cited 1×
“Moreover, direct regulation of signalling mechanisms also appears to be a feature of the action of other steroid receptors, such as that for oestradiol (Migliaccio et al., 1996), and other nuclear hormone receptors (Bost et al., 1997).”
BackgroundMolecular Determinants of Glucocorticoid Receptor Function and Tissue Sensitivity to Glucocorticoids
BAMBERGER, C. M., SCHULTE, H. M., & CHROUSOS, G. P. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-3-245 · Cited by 889 · cited 1×
“The unactivated (unligated) GR is retained in the cytoplasm as a multi-protein complex consisting of heat shock proteins (hsp) (Bamberger et al., 1996) and several kinases of the MAPK signalling system, including Src (Pratt, 1998).”
BackgroundHeck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H. J., Herrlich, P., & Cato, A. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06726.x · Cited by 522 · cited 1×
“The inference was that other transcriptional activators such as AP1 and NFkB, which are probably bound by the GR monomer (Heck et al., 1994), play a key role in mediating the action of glucocorticoids.”
BackgroundMultiple components in an epidermal growth factor-stimulated protein kinase cascade
Ahn, N. G., Seger, R., Bratlien, R. L., Diltz, C. D., Tonks, N. K., & Krebs, E. G. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)64310-1 · Cited by 492
Pratt, W. B. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44252 · Cited by 447 · cited 12×
“We show here that both GR and Src are rapidly released from the hsp90 complex in A549 cells following treatment by dexamethasone.”
BackgroundInfluentialInvolvement of p21ras in activation of extracellular signal-regulated kinase 2
de Vries-Smits, A. M. M., Burgering, B. M. T., Leevers, S. J., Mar shall, C. J., & Bos, J. L. (1992) · Nature · doi:10.1038/357602a0 · Cited by 387 · cited 1×
“…adapter protein Grb2 and the small GTPase p21ras initiates transduction of the mitogenic signalling mechanisms leading to downstream activation of the kinases Raf, MAPK/Erk kinase (Mek) and, subsequently, extracellular signal-regulated kinase (Erk) (Ahn et al., 1991; de Vries-Smits et al., 1992).”
BackgroundNuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
Caelles, C., González-Sancho, J. M., & Muñoz, A. (1997) · Genes & Development · doi:10.1101/gad.11.24.3351 · Cited by 334 · cited 1×
“Recently, other groups have implicated Jnk as an important mediator in A549 cell proliferation (Bost et al., 1997) and suggested that there is cross-talk between this pathway and activation of nuclear hormone receptors (Caelles et al., 1997).”
Background
Cited by
The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease
Oakley, R. H., & Cidlowski, J. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.007 · Cited by 1,068
“When liberated from the GR complex, c-Src activates multiple kinase cascades that lead to the phosphorylation of annexin 1, inhibition of cytosolic phospholipase A2 activity, and impaired release of arachidonic acid (46, 47).”
BackgroundPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
“[181] Natural Tr Additionally, a specific nongenomic mechanism has cells express membrane-bound TGFβ that can delivbeen suggested for suppression of cPLA2 ac- er signals to target cells via a contact-dependent tivity.[136] As a consequence, the production of process.”
BackgroundInfluentialShaker, M. S., Wallace, D. V., Golden, D. B. K., Oppenheimer, J., Bernstein, J. A., Campbell, R. L., Dinakar, C., Ellis, A., Greenhawt, M., Khan, D. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.017 · Cited by 715
Ramamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692
Genomic and nongenomic effects of glucocorticoids
Stahn, C., & Buttgereit, F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0898 · Cited by 594
“Some of the observed anti-inflammatory and immunosuppressive effects, however, occur too fast to be explained by this genomic mode of action”
BackgroundMolecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
Stahn, C., Löwenberg, M., Hommes, D. W., & Buttgereit, F. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.019 · Cited by 419
“actinomycin D-insensitive) mechanism [26].”
BackgroundInfluentialUpdate on glucocorticoid action and resistance
Ito, K., Chung, K. F., & Adcock, I. M. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.032 · Cited by 397
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science's STKE · doi:10.1126/stke.2002.138.re9 · Cited by 369
“GR Inhibition of EGF receptor signaling Lung (106,107)”
BackgroundGlucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action
Buttgereit, F., Straub, R. H., Wehling, M., & Burmester, G. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20583 · Cited by 367
“Croxtall et al ( 32 ) recently reported that epidermal growth factor–stimulated activation of cytosolic phospholipase A2 with subsequent arachidonic acid release can be rapidly inhibited by dexamethasone.”
BackgroundAberrant inflammation and resistance to glucocorticoids in Annexin 1 −/− Mouse
Hannon, R., Croxtall, J. D., Getting, S. J., Roviezzo, F., Yona, S., Paul‐Clark, M. J., Gavins, F. N. E., Perretti, M., Morris, J. F., Buckingham, J. C., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0239fje · Cited by 350
Self-citationBusillo, J. M., & Cidlowski, J. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.005 · Cited by 339
Rapid glucocorticoid effects on immune cells
Buttgereit, F., & Scheffold, A. (2002) · Steroids · doi:10.1016/s0039-128x(01)00171-4 · Cited by 318
Glucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310
Non-genomic effects of glucocorticoids: an updated view
Panettieri, R. A., Schaafsma, D., Amrani, Y., Koziol-White, C., Ostrom, R., & Tliba, O. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.11.002 · Cited by 297
Effects of glucocorticoids on gene transcription
Hayashi, R., Wada, H., Ito, K., & Adcock, I. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.011 · Cited by 277
Glucocorticoids, Sex Hormones, and Immunity
Bereshchenko, O., Bruscoli, S., & Riccardi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01332 · Cited by 261
““Non-genomic” effects of GCs include direct interaction of liganded GR with diverse intracellular mediators and modulating several signaling pathways, including protein kinase C, phosphatidylinositol-specific phospholipase C, and src kinase pathways (38–42).”
Hartmann, K., Koenen, M., Schauer, S., Wittig-Blaich, S., Ahmad, M., Baschant, U., & Tuckermann, J. P. (2016) · Physiological Reviews · doi:10.1152/physrev.00011.2015 · Cited by 247
“To date, there are four subcategories of nongenomic GC actions described: 1) membrane-bound GR (mGR) actions (19), 2) cytosolic GR actions (71, 204), 3) direct physiochemical interactions of GCs with cellular membranes (50), and 4) mitochondrial GR signaling (318).”
Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review
Ahmed, M. H., & Hassan, A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00610-8 · Cited by 234
Bartholome, B., Spies, C. M., Gaber, T., Schuchmann, S., Berki, T., Kunkel, D., Bienert, M., Radbruch, A., Burmester, G., Lauster, R., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0328com · Cited by 229
Mechanisms Generating Diversity in Glucocorticoid Receptor Signaling
Revollo, J. R., & Cidlowski, J. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04986.x · Cited by 220
Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice
Bruscoli, S., Febo, M., Riccardi, C., & Migliorati, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691480 · Cited by 215
“These are characterized mainly by a short delay of action and often involve generation of intracellular second messengers and various signal-transduction cascades, such as phospholipase activation, modulation of cyclic adenosine monophosphate, protein kinase pathways, and Ca mobilization (12, 13).”
BackgroundNon-genomic glucocorticoid effects to provide the basis for new drug developments
Song, I.-H., & Buttgereit, F. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.012 · Cited by 208
Non-genomic effects of glucocorticoids in the neural system
Makara, G. B., & Haller, J. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00012-0 · Cited by 205
New dimension of glucocorticoids in cancer treatment
Lin, K.-T., & Wang, L.-H. (2016) · Steroids · doi:10.1016/j.steroids.2016.02.019 · Cited by 204
“GR has been shown to interact with and alter the activity of several kinases, including JNK [8], Src [9], ERK1/2 [10,11], phosphatidylinositol 3-kinae (PI3K) [12], and protein kinase C (PKC) [13].”
Haller, J., Mikics, É., & Makara, G. B. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.004 · Cited by 203
Annexin‐A1: a pivotal regulator of the innate and adaptive immune systems
D'Acquisto, F., Perretti, M., & Flower, R. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.252 · Cited by 193
“There is ample evidence for an intracellular role of the protein (Futter et al., 1993; Seemann et al., 1997; Alldridge et al., 1999; Croxtall et al., 2000; Solito et al., 2006; White et al., 2006) but in addition it can be exported and act on target cells in an autocrine or paracrine manner.”
BackgroundSelf-citationImmune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses
Franco, L. M., Gadkari, M., Howe, K. N., Sun, J., Kardava, L., Kumar, P., Kumari, S., Hu, Z., Fraser, I. D. C., Moir, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180595 · Cited by 194
“, 2013), proteins that dissociate from the GR–chaperone complex upon glucocorticoid binding (Croxtall et al., 2000), or competition for nuclear coactivators.”
BackgroundAnnexin A1 and the regulation of innate and adaptive immunity
Gavins, F. N. E., & Hickey, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00354 · Cited by 184
“…2003), pain (Marchand et al., 2005), fever (Lim and Pervaiz, 2007), intracellular vesicle trafficking (Gerke et al., 2005), arachidonic acid release (Croxtall et al., 2000), leukocyte migration (Williams et al., 2010), and tissue growth and apoptosis (Petrella et al., 2005; Scannell and Maderna,…”
BackgroundRegulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells
Liberman, A. C., Budziñski, M. L., Sokn, C., Gobbini, R. P., Steininger, A., & Arzt, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00235 · Cited by 181
“On the other hand, binding of GCs to GR can modify the recruitment of different factors such as the multiprotein chaperone complex that participate in many signaling pathways, modifying secondary signaling cascades and, therefore, may further regulate the immune response (78, 83).”
BackgroundSolito, E., Mulla, A., Morris, J. F., Christian, H. C., Flower, R. J., & Buckingham, J. C. (2003) · Endocrinology · doi:10.1210/en.2002-220592 · Cited by 184
Self-citationMolecular mechanisms regulating glucocorticoid sensitivity and resistance
Gross, K. L., Lu, N. Z., & Cidlowski, J. A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.001 · Cited by 180
“Croxtall et al. showed that glucocorticoids stimulate the release of Src kinase from GR heterocomplexes, resulting in lipocortin 1 activation and inhibition of arachidonic acid release (Croxtall et al., 2000).”
BackgroundRole of the hypothalamic–pituitary–adrenal axis in developmental programming of health and disease
Xiong, F., & Zhang, L. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.11.002 · Cited by 177
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn
Löwenberg, M., Tuynman, J., Bilderbeek, J., Gaber, T., Buttgereit, F., van Deventer, S., Peppelenbosch, M., & Hommes, D. (2005) · Blood · doi:10.1182/blood-2004-12-4790 · Cited by 171
General Molecular Biology and Architecture of Nuclear Receptors
Pawlak, M., Lefebvre, P., & Staels, B. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436641 · Cited by 167
“This mechanism seems to be glucocorticoid receptor-dependent but transcription-independent [279,280].”
BackgroundCorticosteroids in Acute Lung Injury: The Dilemma Continues
Mokra, D., Mikolka, P., Kosutova, P., & Mokry, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194765 · Cited by 166
“Non-genomic interactions can be classified into three categories: (1) non-specific interactions of CS with cellular membranes which change physicochemical properties of the membrane, mineral transport across the cell membrane, and production of adenosine triphosphate (ATP) leading to immune cell suppression [39,44]; (…”
BackgroundLöwenberg, M., Verhaar, A. P., Bilderbeek, J., van Marle, J., Buttgereit, F., Peppelenbosch, M. P., van Deventer, S. J., & Hommes, D. W. (2006) · EMBO reports · doi:10.1038/sj.embor.7400775 · Cited by 157
“GCs also evoke nongenomic effects on cellular function, which occur in minutes (Baus et al, 1996; Croxtall et al, 2000; Rhen & Cidlowski, 2005).”
BackgroundExploiting the Annexin A1 pathway for the development of novel anti‐inflammatory therapeutics
Perretti, M., & Dalli, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00483.x · Cited by 154
Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression
Löwenberg, M., Verhaar, A. P., van den Brink, G. R., & Hommes, D. W. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.02.001 · Cited by 189
Flaherty, R. L., Owen, M., Fagan-Murphy, A., Intabli, H., Healy, D., Patel, A., Allen, M. C., Patel, B. A., & Flint, M. S. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0823-8 · Cited by 171
“A multi-complex of proteins including heat shock proteins and Src kinase is associated with the GR in its ligand-unbound state [26, 27].”
Glucocorticoid receptors: finding the middle ground
Desmet, S. J., & De Bosscher, K. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88886 · Cited by 147
“These accessory proteins set in motion secondary signaling cascades such as inhibition of EGFR signaling through the actions of c-Src (1, 2, 88).”
Alldridge, L. C., & Bryant, C. E. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00310-0 · Cited by 163
Different glucocorticoids vary in their genomic and non‐genomic mechanism of action in A549 cells
Croxtall, J. D., Van Hal, P. T. W., Choudhury, Q., Gilroy, D. W., & Flower, R. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704474 · Cited by 148
“In A549 cells pre-treated with either the benzoquinone ansamycin geldanamycin, which selectively binds hsp90 and prevents nuclear translocation of GR, the dexamethasone-induced inhibition of cPLA2 is completely una ected (Croxtall et al., 2000).”
BackgroundMethodInfluentialSelf-citationAnnexins — Modulators of EGF receptor signalling and trafficking
Grewal, T., & Enrich, C. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.031 · Cited by 156
Glucocorticoid-Induced Apoptosis of Healthy and Malignant Lymphocytes
Smith, L. K., & Cidlowski, J. A. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)82001-1 · Cited by 144
“The activation of Src required ligand-bound GR, but was independent of transactivation (Croxtall et al., 2000).”
BackgroundMolecular mechanism of glucocorticoid resistance in inflammatory bowel disease
Iudicibus, S. D., Franca, R., Martelossi, S., Ventura, A., & Decorti, G. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i9.1095 · Cited by 152
van der Goes, M. C., Jacobs, J. W. G., & Bijlsma, J. W. J. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4686 · Cited by 163
“Mechanisms of action Th e eff ects of glucocorticoids are thought to be mediated by diff erent mechanisms [14-19].”
BackgroundOu, Z., Zhao, Y., Zhu, L., Huang, L., Ma, Y., Ma, C., Luo, C., Zhu, Z., Yuan, Z., Wu, J., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109347 · Cited by 136
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Specificity and sensitivity of glucocorticoid signaling in health and disease
Cain, D. W., & Cidlowski, J. A. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.007 · Cited by 127
Chung, K. F., Caramori, G., & Adcock, I. M. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0682-z · Cited by 147
“In addition, the classical receptor is associated with a number of kinases and phosphatases within the inactive GR-hsp90 complex [14, 15].”
BackgroundMarchetti, M. C., Marco, B. D., Cifone, M. G., Migliorati, G., & Riccardi, C. (2002) · Blood · doi:10.1182/blood-2002-06-1779 · Cited by 143
Buttgereit, F., Saag, K. G., Cutolo, M., da Silva, J. A. P., & Bijlsma, J. W. J. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510017706 · Cited by 124
“In the case of the GCR these functions are realized by chaperones such as hsp90, hsp70, hsp56, or hsp40 and co-chaperones such as imunophilins or several kinases of the mitogen-activated protein kinase (MAPK) signalling system, including Src, to name just a few (21, 54, 55).”
BackgroundSolito, E., Christian, H., Festa, M., Mulla, A., Tierney, T., Flower, R. J., & Buckingham, J. C. (2006) · The FASEB Journal · doi:10.1096/fj.05-5319fje · Cited by 126
Self-citationOptimized glucocorticoid therapy: teaching old drugs new tricks
Strehl, C., & Buttgereit, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.026 · Cited by 118
McLaughlin, F., Mackintosh, J., Hayes, B., McLaren, A., Uings, I., Salmon, P., Humphreys, J., Meldrum, E., & Farrow, S. N. (2002) · Bone · doi:10.1016/s8756-3282(02)00737-8 · Cited by 126
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma
Horváth, G., & Wanner, A. (2005) · European Respiratory Journal · doi:10.1183/09031936.06.00048605 · Cited by 127
Rose, A. J., Vegiopoulos, A., & Herzig, S. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.02.010 · Cited by 130
Bernardi, R. J., Trump, D. L., Yu, W., McGuire, T. F., Hershberger, P. A., & Johnson, C. S. (2001) · PubMed · Cited by 113
Effects of Glucocorticoids in the Immune System
Oppong, E. K., & Cato, A. C. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2895-8_9 · Cited by 122
“These actions of glucocorticoids involve modulation of signaling pathways, and they occur within seconds to minutes and are insensitive to transcriptional and translation inhibitors [ 36 ].”
BackgroundAldosterone Stimulates Epidermal Growth Factor Receptor Expression
Krug, A. W., Großmann, C., Schuster, C., Freudinger, R., Mildenberger, S., Govindan, M. V., & Gekle, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308134200 · Cited by 122
Molecular mechanisms of immunomodulatory activity of glucocorticoids
Riccardi, C., Bruscoli, S., & Migliorati, G. (2002) · Pharmacological Research · doi:10.1006/phrs.2002.0969 · Cited by 122
Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance
Troncoso, R., Paredes, F., Parra, V., Gatica, D., Vásquez-Trincado, C., Quiroga, C., Bravo-Sagua, R., López-Crisosto, C., Rodriguez, A. E., Oyarzún, A. P., et al. (2014) · Cell Cycle · doi:10.4161/cc.29272 · Cited by 108
Watts, A. M., Cripps, A. W., West, N. P., & Cox, A. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00294 · Cited by 121
Progesterone metabolites in breast cancer
Wiebe, J. P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01010 · Cited by 103
“…for estradiol (Watson et al. 1999, Keshamouni et al. 2002, Purves-Tyson & Keast 2004, Simoncini et al. 2004), corticosteroids (Wehling 1997, Croxtall et al. 2000), 3aHP (Dhanvantari & Wiebe 1994, Beck et al. 1997, Wiebe 1997), and neurosteroids such as the P metabolite,…”
BackgroundDefining the role of glucocorticoids in inflammation
Ronchetti, S., Migliorati, G., Bruscoli, S., & Riccardi, C. (2018) · Clinical Science · doi:10.1042/cs20171505 · Cited by 109
Malcher‐Lopes, R., Franco, A. J., & Tasker, J. G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.033 · Cited by 97
“Croxtall and collaborators have demonstrated that dexamethasone rapidly inhibits cPLA2 activation and arachidonic acid release downstream from the EGF receptor by blocking the activation of MAPK/ERK kinase (MEK) and ERK (Ahn et al., 1991; Croxtall et al., 2000; Croxtall et al., 1996; Croxtall et al., 1995; Croxtall et…”
BackgroundSpies, C. M., Strehl, C., van der Goes, M. C., Bijlsma, J. W. J., & Buttgereit, F. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.11.002 · Cited by 113
The complex understanding of Annexin A1 phosphorylation
D’Acunto, C. W., Gbelcová, H., Festa, M., & Ruml, T. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.09.020 · Cited by 89
Matthews, L., Berry, A., Ohanian, V., Ohanian, J., Garside, H., & Ray, D. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0154 · Cited by 88
“Because src family kinases have previously been implicated in Gc action in A549 cells (8) and are a potential mediating step between GR activation and both PI3K function and caveolin phosphorylation, we fractionated cell homogenates to look for segregation of GR with plasma membrane fractions.”
BackgroundKrug, A. W., Schuster, C., Gassner, B., Freudinger, R., Mildenberger, S., Troppmair, J., & Gekle, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208851200 · Cited by 87
Genomic and non-genomic actions of glucocorticoids in asthma
Alangari, A. (2010) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.65040 · Cited by 101
“When glucocorticoids bind their own receptors in the cytosol, some GR protein complex components, like src, dissociate and block the EGFmediated cPLA2 activation and subsequently arachidonic acid production.[78,79] Although several in vitro studies and animal studies have demonstrated decrease in baseline and postchal…”
Ouatas, T., Halverson, D. O., & Steeg, P. S. (2003) · PubMed · Cited by 82
Annexins in Translational Research: Hidden Treasures to Be Found
Schloer, S., Pajonczyk, D., & Rescher, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061781 · Cited by 83
A gradient of glucocorticoid sensitivity among helper T cell cytokines
Banuelos, J., & Lu, N. Z. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.05.002 · Cited by 79
“For example, Src, as a kinase, activates lipocortin-1 and inhibits arachidonic acid release [55].”
BackgroundCorticosteroids in management of anaphylaxis; a systematic review of evidence
Liyanage, C. K., Galappatthy, P., & Seneviratne, S. L. (2017) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.15 · Cited by 94
Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome
Schijvens, A. M., ter Heine, R., de Wildt, S. N., & Schreuder, M. F. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3929-z · Cited by 92
Origin and functional activity of the membrane-bound glucocorticoid receptor
Strehl, C., Gaber, T., Löwenberg, M., Hommes, D. W., Verhaar, A. P., Schellmann, S., Hahne, M., Fangradt, M., Wagegg, M., Hoff, P., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30637 · Cited by 78
Nontranscriptional actions of the glucocorticoid receptor
Limbourg, F. P., & Liao, J. K. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0418-y · Cited by 92
“For example, osteocyte apoptosis and bone loss is prevented by the androgen and estrogen steroid receptors through nontranscriptional activation of protein kinase Src and mitogen-activated protein kinase [65, 66].”
BackgroundInfluentialDeng, Q., Riquelme, D., Trinh, L., Low, M. J., Tomić, M., Stojilkovic, S., & Aguilera, G. (2015) · Endocrinology · doi:10.1210/en.2015-1265 · Cited by 77
Nongenomic actions of adrenal steroids in the central nervous system
Evanson, N. K., Herman, J. P., Sakai, R. R., & Krause, E. G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.02000.x · Cited by 76
Sionov, R. V., Spokoini, R., Kfir‐Erenfeld, S., Cohen, O., & Yefenof, E. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00406-5 · Cited by 88
“In the A549 human adenocarcinoma cell line, Dex inhibited epidermal growth factor (EGF)‐stimulated cytosolic phospholipase A2 activation and arachidonic acid release within minutes by blocking the recruitment of the Grb2 adaptor molecule to the activated EGF receptor (Croxtall et al., 2000).”
BackgroundInfluentialPiette, C., Deprez, M., Roger, T., Noël, A., Foidart, J., & Munaut, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014589 · Cited by 86
Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells
Gekle, M., Freudinger, R., Mildenberger, S., & Silbernagl, S. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00159.2001 · Cited by 75
From NSAIDs to Glucocorticoids and Beyond
Sinniah, A., Yazid, S., & Flower, R. (2021) · Cells · doi:10.3390/cells10123524 · Cited by 91
“GCs induce rapid nongenomic mobilisation and secretion of AnxA1 at the cell surface and a slower (2–4 h) upregulation of the AnxA1 gene transcription through genomic mechanisms during the inflammatory process [88].”
BackgroundSelf-citationJames, C. G., Ulici, V., Tuckermann, J. P., Underhill, T. M., & Beier, F. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-205 · Cited by 76
“Specific non-genomic GC regulation occurs through the classical GR and its cytoplasmic heteroprotein complex or non-classical GRs such as membrane GR [106-109].”
BackgroundGlucocorticoid-independent modulation of GR activity: Implications for immunotherapy
Hapgood, J. P., Avenant, C., & Moliki, J. M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.002 · Cited by 83
“…T-cell receptor (TCR) (Bartis et al., 2007; Bartis et al., 2006; Harr et al., 2009; Lowenberg et al., 2006b), fibroblast growth factor receptor-1 (Croxtall et al., 2000), epidermal growth factor receptor (Croxtall et al., 2000) and insulin receptor pathways (Lowenberg et al., 2006a),…”
BackgroundEffects of Glucocorticoids on Apoptosis and Clearance of Apoptotic Cells
McColl, A., Michlewska, S., Dransfield, I., & Rossi, A. G. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.224 · Cited by 79
“Investigations by Croxtall and colleagues have implicated GCR-dependent effects of dexamethasone via altered phosphorylation status of annexin I, leading to inhibition of cPLA2 activation and arachidonic acid release[54].”
BackgroundKomatsuzaki, Y., Hatanaka, Y., Murakami, G., Mukai, H., Hojo, Y., Saito, M., Kimoto, T., & Kawato, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034124 · Cited by 67
“DEX rapidly acts to inhibit recruitment of MAPK to activate EGF receptors in adenocarcinoma cell [35].”
BackgroundAbsence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines
Vishwanatha, J. K., Salazar, E., & Gopalakrishnan, V. K. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-8 · Cited by 67
“Substantial evidence suggests a role for annexin I in glucocorticoid-induced immunosuppression [6,7] and MAPK/ERK pathway [7,8].”
BackgroundAttenuation of glucocorticoid functions in an Anx-A1-/- cell line
Croxtall, J. D., Gilroy, D. W., Solito, E., Choudhury, Q., Ward, B. J., Buckingham, J. C., & Flower, R. (2003) · Biochemical Journal · doi:10.1042/bj20021856 · Cited by 67
Self-citationJewell, C. M., Scoltock, A. B., Hamel, B. L., Yudt, M. R., & Cidlowski, J. A. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1116 · Cited by 64
“Dimerization and DNA binding Initial studies of the dimerization domain mutations demonstrated that liver extracts from the GR mouse could not bind DNA nor form homodimers (11, 20).”
BackgroundMechanisms of glucocorticoid action and insensitivity in airways disease
Boardman, C., Chachi, L., Gavrila, A., Keenan, C. R., Perry, M. M., Xia, Y., Meurs, H., & Sharma, P. K. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.008 · Cited by 82
“the regulator proteins including the MAPK signaling cascade by affecting interaction of p21Ras with Raf [63].”
BackgroundAnnexin A1 processing is associated with caspase‐dependent apoptosis in BZR cells
Debret, R., Btaouri, H. E., Duca, L., Rahman, I., Radke, S., Haye, B., Sallenave, J., & Antonicelli, F. D. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00570-2 · Cited by 73
Fahnenstich, J., Nandy, A., Milde-Langosch, K., Schneider‐Merck, T., Walther, N., & Gellersen, B. (2003) · Molecular Human Reproduction · doi:10.1093/molehr/gag080 · Cited by 76
“Liganded GR or PR can modulate the MAPK pathway by interaction with cytosolic signalling molecules (Migliaccio et al., 1998; Croxtall et al., 2000; Boonyaratanakornkit et al., 2001).”
BackgroundRegulatory effects of dexamethasone on NK and T cell immunity
Chen, L., Jondal, M., & Yakimchuk, K. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0418-0 · Cited by 69
“In addi- tion to genomic mechanisms, GCs also elicit rapid effects mediated via the cell membrane, including regulation of signaling pathways (Croxtall et al. 2000).”
BackgroundMolecular mechanisms of glucocorticoid action in mast cells
Oppong, E. K., Flink, N., & Cato, A. C. B. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.05.014 · Cited by 67
“These actions of glucocorticoids occur within seconds to minutes and are insensitive to transcriptional and translational inhibitors (Croxtall et al., 2000).”
Backgroundde Graauw, M., Cao, L., Winkel, L. C. J., van Miltenburg, M. H. A. M., Dévédec, S. E. L., Klop, M.-L., Yan, K., Pont, C., Rogkoti, V.-M., Tijsma, A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.219 · Cited by 63
Cheung, L. W. T., Leung, K. W., Wong, C. K. C., Wong, R. N., & Wong, A. S. T. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq300 · Cited by 61
Strehl, C., & Buttgereit, F. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12364 · Cited by 63
Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis
Damazo, A. S., Sampaio, A. L. F., Nakata, C. M. D. A. G., Flower, R. J., Perretti, M., & Oliani, S. M. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-59 · Cited by 64
“AnxA1 has been implicated in many aspects of cell physiology including regulation of cell growth [37] and differentiation [38], signal transduction and arachidonic acid release [39], as well as intracellular vesicle trafficking [40].”
BackgroundSelf-citation
Metadata
- Authors
- Croxtall, J. D., Choudhury, Q., & Flower, R. J.
- Affiliations
- Queen Mary University of London (GB)
- Corresponding author
- Croxtall, Jamie D
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-05
- Volume
- 130
- Issue
- 2
- Pages
- 289-298
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC1572055
- OpenAlex
- W2076179697
- Cited by
- 332
- References
- 42
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 12 · 2018: 11 · 2017: 9 · 2016: 12 · 2015: 12 · 2014: 15 · 2013: 18 · 2012: 17
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- glucocorticoids, dexamethasone, epidermal growth factor receptor, Grb2, p21ras, Raf, ERK signaling, cytosolic phospholipase A2, arachidonic acid release, annexin A1, glucocorticoid receptor, receptor tyrosine kinase signaling, A549 cells
- MeSH terms
- Binding, Competitive, Dexamethasone, Enzyme Activation, Glucocorticoids, Humans, Phospholipases A, Phosphorylation, Protein Conformation, Proteins, Receptors, Glucocorticoid, Transcription, Genetic, Tumor Cells, Cultured, Signal Transduction, Annexin A1, MAP Kinase Signaling System, Adaptor Proteins, Signal Transducing, GRB2 Adaptor Protein, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.